Avrobio (NASDAQ: AVRO)
Some price data may be temporarily unavailable.
Key Data Points
Avrobio Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Avrobio Company Info
Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firm's clinical-stage programs include Fabry, Gaucher Type 1, Hunter syndrome Gaucher Type 3, Pompe, and Cystinosis. The company was founded by Geoff Mackay, Kim Warren, Christopher Mason, and Jeffrey Medin in 2015 and is headquartered in Cambridge, MA.
News & Analysis
Here's Why Avrobio Fell as Much as 16.4% Today
The small-cap biopharmaceutical company announced a public stock offering.
Why Seattle Genetics, AVROBIO, and First Majestic Silver Jumped Today
Despite declines in the broader market, good news lifted these shares.
Here's Why Avrobio Rose as Much as 19.9% Today
The gene therapy developer announced higher-than-expected demand for its public stock offering.
Why Crocs, Golden Star Resources, and AVROBIO Jumped Today
Stocks made tiny gains to begin the week.
Financial Health
General
Q4 2024 | YoY Change |
---|
Revenue Growth Rate
Earnings Per Share Growth Rate
Assets
Q4 2024 | YoY Change |
---|
Liabilities
Q4 2024 | YoY Change |
---|
Ratios
Q4 2024 | YoY Change |
---|
Cash Flow
Q4 2024 | YoY Change |
---|
Valuation
Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | YoY Change |
---|
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.